Efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancers: results from the phase II LIBRETTO-321 study

BACKGROUND: Selpercatinib, a highly selective and potent REarranged during Transfection (RET) kinase inhibitor, is effective in advanced RET-altered thyroid cancer (TC). However, the efficacy and safety in Chinese patients are unknown. PATIENTS AND METHODS: In the open-label, multi-center phase II L...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Xiangqian, Ji, Qinghai, Sun, Yuping, Ge, Minghua, Zhang, Bin, Cheng, Ying, Lei, Shangtong, Shi, Feng, Guo, Ye, Li, Linfa, Chen, Lu, Shao, Jingxin, Zhang, Wanli, Gao, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434679/
https://www.ncbi.nlm.nih.gov/pubmed/36062046
http://dx.doi.org/10.1177/17588359221119318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434679/
https://www.ncbi.nlm.nih.gov/pubmed/36062046
http://dx.doi.org/10.1177/17588359221119318

Ejemplares similares